Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

armaceuticals, Inc. Consolidated Statements of Operations (unaudited) Three Months Ended Six Months Ended June 30, June 30, ----------------- ----------------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenues: Research grants $324,778 $118,797 $407,790 $605,463 Collaborative research agreements 100,000 50,000 100,000 50,000 ------- ------ ------- ------ Total revenues 424,778 168,797 507,790 655,463 Operating expenses: Research and development 10,528,482 6,220,482 19,327,064 13,125,858 Marketing 475,062 913,916 785,348 1,279,484 General and administrative 1,871,309 1,521,446 3,919,809 3,258,497 --------- --------- --------- --------- Total operating expenses 12,874,853 8,655,844 24,032,221 17,663,839 ---------- --------- ---------- ---------- Loss from operations (12,450,075) (8,487,047) (23,524,431) (17,008,376) Interest income and other, net 88,070 433,750 275,038 1,015,034 ------ ------- ------- --------- Net loss $(12,362,005) $(8,053,297) $(23,249,393) $(15,993,342) ============ =========== ============ ============ Basic and diluted net loss per share $(0.37) $(0.29) $(0.73) $(0.57)
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... development, opportunities for business growth, COLUMBUS, Ohio, ... and universities increased academic research expenditures in 2006,to ... ever into high,technology R&D sectors throughout the Buckeye ... tech research, development and,commercialization, especially in the advanced ...
... MDVN ) today announced that David Hung, M.D., president ... Rodman & Renshaw 9th,Annual Healthcare Conference on Tuesday, November ... Palace Hotel. Dr. Hung will provide an overview ... Alzheimer,s and Huntington,s,diseases and MDV3100 for prostate cancer. ...
... SAN DIEGO, Oct. 31 Anadys Pharmaceuticals,Inc. (Nasdaq: ... the Acumen,BioFin(TM) Rodman & Renshaw 9th Annual Healthcare Conference ... p.m. PST). The conference is being,held at the New ... Chief Executive Officer of Anadys,Pharmaceuticals, Inc. will present an ...
Cached Biology Technology:Ohio Academic Institutions Increase Research and Development Investments 2Ohio Academic Institutions Increase Research and Development Investments 3Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference 2
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... the 1930s to estimate the abundance of fish has ... effective at reducing poaching of elephants, African buffaloes and ... , "Wildlife within protected areas is under increasing ... many argue that enforcement within protected areas is not ...
... University School of Medicine and Albany Medical College, ... a mini symposium held today at the 14th ... that a blend of natural botanical products called ... IGF-1, which is responsible for growing human cartilage ...
... the Japanese villages of Taiji and Futo, a consortium of ... campaign to end the practices through public awareness and by ... to the hunts. The "Act for Dolphins" campaign--which includes members ... Association of Zoos and Aquariums (WAZA) --maintains that the hunts, ...
Cached Biology News:Serengeti patrols cut poaching of buffalo, elephants, rhinos 2Gene therapy research switches off joint inflammation; switches on genetic process of joint repair 2Renewed dolphin slaughter prompts new campaign 2Renewed dolphin slaughter prompts new campaign 3
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
... been developed specifically for the stabilization ... microwell plates/strips. Coating Stabilizer maintains ... antibody or protein antigen portion of ... is filtered at 0.2 microns., ,Contents: ...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: